摘要
戊苯那嗪是一种新型、高选择性囊泡单胺转运体2抑制剂, 2017年4月被美国食品和药物管理局批准用于治疗成人迟发性运动障碍。在为期6周的短期治疗和持续48周的长期治疗临床试验中,戊苯那嗪均显示出对迟发性运动障碍良好的治疗效果,其常见的不良反应有嗜睡和头痛等。
Valbenazine,a novel and highly selective vesicular monoamine transporter 2(VMAT2)inhibitor,was approved by U.S.Food and Drug Administration for treating tardive dyskinesia in adults in April 2017.Clinical trials showed that valbenazine was effective in treating tardive dyskinesia both in 6-week short-term studies and 48-week long-term extension trials,and the common adverse reactions of valbenazine were somnolence,headache,and so on.
作者
程海婷
赵明
刘洪涛
CHENG Hai-ting;ZHAO Ming;LIU Hong-tao(Department of Pharmacy,Beijing Stomatological Hospital,Capital Medical University,BEIJING 100050,China;Department of Pharmacy/National Center of Gerontology,Beijing Hospital,BEIJING 100730,China)
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2019年第5期271-275,共5页
Chinese Journal of New Drugs and Clinical Remedies
关键词
戊苯那嗪
运动障碍
囊泡单胺转运蛋白质类
药理作用
valbenazine
movement disorders
vesicular monoamine transport proteins
pharmacologic actions
